MedPath

Valneva Expands Chikungunya Vaccine Access in Asia Through Collaboration with Serum Institute of India

Valneva, in partnership with the Serum Institute of India (SII), is enhancing access to its chikungunya vaccine in Asia. This collaboration includes creating a stockpile of 100,000 doses for clinical trials and emergency responses, aiming to bolster regional health security and ensure affordable vaccine availability to those in need.

Valneva and the Serum Institute of India (SII) have announced a significant collaboration to expand access to Valneva's chikungunya vaccine in Asia. This partnership will see SII making available a stockpile of 100,000 doses of the vaccine to the Coalition for Epidemic Preparedness Innovations (CEPI). This stockpile is intended to serve as an 'investigational ready reserve' for use in clinical trials within the region, potentially offering valuable data on the vaccine's efficacy among local populations.
Additionally, a safety stock of up to 100,000 doses will be directly accessible to CEPI, at CEPI's expense, for potential deployment in response to future chikungunya outbreaks in Asia. Dr. Richard Hatchett, CEO of CEPI, emphasized the importance of this initiative, stating, "Chikungunya continues to pose a troubling and debilitating danger to the world, including in Asia, with climate change threatening to worsen its spread."
Valneva's chikungunya vaccine is notable for being the world’s first and only licensed chikungunya vaccine, currently approved in the U.S., Europe, and Canada for individuals 18 years of age and older. Efforts are underway to extend its approval to individuals 12 years of age and older.
This initiative is part of Valneva's broader strategy, supported by CEPI and the European Union’s Horizon program, to increase the vaccine's accessibility in Low- and Middle-Income Countries (LMICs). A similar partnership with Brazil’s Instituto Butantan (IB) aims to expand vaccine access in the Americas, with ongoing reviews by the Brazilian Health Regulatory Agency (ANVISA).
Chikungunya virus (CHIKV), transmitted by Aedes mosquitoes, causes symptoms including fever, severe joint and muscle pain, headache, nausea, fatigue, and rash. The disease has seen a rapid spread since 2004, with over 3.7 million cases reported in the Americas between 2013 and 2023. The World Health Organization (WHO) has identified chikungunya as a major public health concern, with the potential for increased spread due to climate change.
This collaboration between Valneva and SII represents a critical step forward in combating chikungunya, particularly in Asia, by ensuring the availability of an effective vaccine to those most in need and enhancing regional health security.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Valneva's Ixchiq: First Chikungunya Vaccine

The FDA has granted approval to Valneva's Ixchiq vaccine, making it the first-ever vaccine for the chikungunya virus, a mosquito-borne disease causing severe joint pain.
Ixchiq is approved for adults 18 and over at increased risk of chikungunya exposure, demonstrating a 98.9% antibody response rate in clinical trials 28 days post-vaccination.

FDA Approves Bavarian Nordic's Vimkunya, First Chikungunya Vaccine for Adolescents

The FDA has approved Vimkunya, a chikungunya vaccine developed by Bavarian Nordic, for individuals aged 12 and older.
Vimkunya is the first virus-like particle (VLP) single-dose chikungunya vaccine approved in the U.S., offering a new preventative option.

Largest-Ever Study Launched to Track Chikungunya Burden in East Africa

A large-scale study, ACHIEVE, has been launched in East Africa to investigate the burden of chikungunya in Kenya and Tanzania.
The study will screen patients with fever or neurological symptoms for chikungunya at healthcare facilities across both countries starting in 2025.

Roche's Vabysmo Gains Reimbursement in China, Eyes Expansion in Asia

Roche's Vabysmo will be included in China's National Reimbursement Drug List (NRDL) from 2025 to 2026, covering three ophthalmic indications.
This NRDL listing is expected to significantly enhance Vabysmo's accessibility and market penetration within China.

Valneva Seeks FDA Approval to Extend IXCHIQ Chikungunya Vaccine to Adolescents

Valneva has submitted a label extension application to the FDA for its IXCHIQ vaccine, seeking approval for use in adolescents aged 12-17 years.
The application includes data demonstrating 99.1% of adolescents showed a high and sustained immune response after a single dose.

Valneva's Chikungunya Vaccine Shows Two-Year Antibody Persistence in Adults

Valneva's single-dose chikungunya vaccine (VLA1553) demonstrates sustained antibody persistence two years post-vaccination in adults aged 18 and above.
The open-label Phase 3b trial (VLA1553-303) evaluated the long-term safety and immunogenicity of the vaccine, building on previous Phase 3 results.

Valneva and LimmaTech Receive FDA Fast Track Designation for Shigella Vaccine Candidate

Valneva and LimmaTech's Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate, has received FDA Fast Track designation, aimed at expediting the development of treatments for serious conditions.
Shigellosis, caused by Shigella bacteria, affects up to 165 million people annually, resulting in approximately 600,000 deaths, particularly impacting children in low- and middle-income countries.

Antengene's Xpovio Receives Thailand FDA Approval for Multiple Myeloma

Thailand FDA approves Xpovio (selinexor) for multiple myeloma, marking its availability in nine APAC markets.
Xpovio, a selective XPO1 inhibitor, is approved for use in combination with bortezomib and dexamethasone after one prior therapy.

Vietnam Launches Nationwide Dengue Fever Vaccination Program with Qdenga

Vietnam has initiated a nationwide dengue fever vaccination program, the first of its kind in the country, targeting individuals aged four and above.
The vaccine being deployed is Qdenga, developed by Takeda Pharmaceutical, which has demonstrated up to 80% efficacy against all four dengue virus types.

Valneva Seeks to Expand IXCHIQ Chikungunya Vaccine Label to Adolescents in Europe and Canada

Valneva has submitted label extension applications to the EMA and Health Canada for its chikungunya vaccine, IXCHIQ, to include adolescents aged 12-17.
The applications are supported by Phase 3 data demonstrating a 99.1% immune response in adolescents following a single dose of IXCHIQ.

Reference News

[1]
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India
finance.yahoo.com · Dec 19, 2024

SII and CEPI collaborate to stockpile 100,000 doses of Valneva's chikungunya vaccine for clinical trials and outbreak re...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy